Alnylam Pharmaceuticals annual stock-based compensation
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Stock-Based Compensation Growth & History (ALNY)
Alnylam Pharmaceuticals's stock-based compensation was $348.2M for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $348.2M | $76.2M | +27.99% |
| 2024 | 2024-12-31 | $272.1M | $50.4M | +22.74% |
| 2023 | 2023-12-31 | $221.7M | −$9.0M | −3.89% |
| 2022 | 2022-12-31 | $230.6M | $64.9M | +39.18% |
| 2021 | 2021-12-31 | $165.7M | $25.8M | +18.48% |
| 2020 | 2020-12-31 | $139.9M | −$35.0M | −20.00% |
| 2019 | 2019-12-31 | $174.8M | $17.1M | +10.83% |
| 2018 | 2018-12-31 | $157.8M | $64.9M | +69.96% |
| 2017 | 2017-12-31 | $92.8M | $17.3M | +22.89% |
| 2016 | 2016-12-31 | $75.5M | $29.7M | +64.97% |
| 2015 | 2015-12-31 | $45.8M | $12.7M | +38.48% |
| 2014 | 2014-12-31 | $33.1M | $12.4M | +59.69% |
| 2013 | 2013-12-31 | $20.7M | $8.3M | +67.50% |
| 2012 | 2012-12-31 | $12.4M | −$4.3M | −25.88% |
| 2011 | 2011-12-31 | $16.7M | −$2.4M | −12.77% |
| 2010 | 2010-12-31 | $19.1M | −$609,000 | −3.09% |
| 2009 | 2009-12-31 | $19.7M | $1.7M | +9.44% |
| 2008 | 2008-12-31 | $18.0M | — | — |
Alnylam Pharmaceuticals quarterly stock-based compensation
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $86.6M | −$25.1M | −22.43% |
| Q1 2026 | 2026-03-31 | $70.2M | $13.4M | +23.70% |
| Q4 2025 | 2025-12-31 | $71.6M | −$20.0M | −21.84% |
| Q3 2025 | 2025-09-30 | $108.2M | $62.4M | +136.25% |
| Q2 2025 | 2025-06-30 | $111.7M | $22.4M | +25.08% |
| Q1 2025 | 2025-03-31 | $56.7M | $11.4M | +25.06% |
| Q4 2024 | 2024-12-31 | $91.6M | $49.7M | +118.23% |
| Q3 2024 | 2024-09-30 | $45.8M | −$18.1M | −28.36% |
| Q2 2024 | 2024-06-30 | $89.3M | $13.5M | +17.79% |
| Q1 2024 | 2024-03-31 | $45.3M | $5.4M | +13.52% |
| Q4 2023 | 2023-12-31 | $42.0M | −$773,000 | −1.81% |
| Q3 2023 | 2023-09-30 | $63.9M | −$64.2M | −50.10% |
| Q2 2023 | 2023-06-30 | $75.8M | $45.3M | +148.77% |
| Q1 2023 | 2023-03-31 | $39.9M | $10.7M | +36.37% |
| Q4 2022 | 2022-12-31 | $42.8M | −$1.8M | −4.07% |
| Q3 2022 | 2022-09-30 | $128.1M | $94.8M | +283.97% |
| Q2 2022 | 2022-06-30 | $30.5M | −$1.6M | −5.01% |
| Q1 2022 | 2022-03-31 | $29.3M | −$26.4M | −47.40% |
| Q4 2021 | 2021-12-31 | $44.6M | $10.3M | +30.07% |
| Q3 2021 | 2021-09-30 | $33.4M | −$3.9M | −10.46% |
| Q2 2021 | 2021-06-30 | $32.1M | −$1.7M | −4.97% |
| Q1 2021 | 2021-03-31 | $55.7M | $21.1M | +61.06% |
| Q4 2020 | 2020-12-31 | $34.3M | −$31.9M | −48.22% |
| Q3 2020 | 2020-09-30 | $37.3M | −$8.7M | −19.01% |
| Q2 2020 | 2020-06-30 | $33.8M | $3.2M | +10.30% |
| Q1 2020 | 2020-03-31 | $34.6M | $2.5M | +7.95% |
| Q4 2019 | 2019-12-31 | $66.2M | $38.2M | +136.65% |
| Q3 2019 | 2019-09-30 | $46.0M | −$41.9M | −47.69% |
| Q2 2019 | 2019-06-30 | $30.6M | $8.4M | +37.60% |
| Q1 2019 | 2019-03-31 | $32.0M | $12.4M | +63.56% |
| Q4 2018 | 2018-12-31 | $28.0M | $856,000 | +3.16% |
| Q3 2018 | 2018-09-30 | $88.0M | $62.0M | +238.87% |
| Q2 2018 | 2018-06-30 | $22.2M | −$1.8M | −7.44% |
| Q1 2018 | 2018-03-31 | $19.6M | $3.9M | +24.60% |
| Q4 2017 | 2017-12-31 | $27.1M | $6.5M | +31.31% |
| Q3 2017 | 2017-09-30 | $26.0M | $10.4M | +66.58% |
| Q2 2017 | 2017-06-30 | $24.0M | $8.2M | +51.93% |
| Q1 2017 | 2017-03-31 | $15.7M | −$7.8M | −33.06% |
| Q4 2016 | 2016-12-31 | $20.7M | $5.1M | +33.06% |
| Q3 2016 | 2016-09-30 | $15.6M | $3.7M | +31.51% |
| Q2 2016 | 2016-06-30 | $15.8M | $5.6M | +55.38% |
| Q1 2016 | 2016-03-31 | $23.5M | $15.2M | +185.09% |
| Q4 2015 | 2015-12-31 | $15.5M | $2.1M | +15.49% |
| Q3 2015 | 2015-09-30 | $11.8M | $5.5M | +86.52% |
| Q2 2015 | 2015-06-30 | $10.2M | $2.5M | +32.54% |
| Q1 2015 | 2015-03-31 | $8.2M | $2.6M | +47.31% |
| Q4 2014 | 2014-12-31 | $13.4M | $8.0M | +148.58% |
| Q3 2014 | 2014-09-30 | $6.4M | −$2.5M | −28.19% |
| Q2 2014 | 2014-06-30 | $7.7M | $4.3M | +127.42% |
| Q1 2014 | 2014-03-31 | $5.6M | $2.5M | +81.82% |
| Q4 2013 | 2013-12-31 | $5.4M | $2.7M | +98.60% |
| Q3 2013 | 2013-09-30 | $8.8M | $5.5M | +161.22% |
| Q2 2013 | 2013-06-30 | $3.4M | $281,000 | +9.08% |
| Q1 2013 | 2013-03-31 | $3.1M | −$81,000 | −2.57% |
| Q4 2012 | 2012-12-31 | $2.7M | −$1.4M | −33.32% |
| Q3 2012 | 2012-09-30 | $3.4M | −$872,000 | −20.48% |
| Q2 2012 | 2012-06-30 | $3.1M | −$1.1M | −26.53% |
| Q1 2012 | 2012-03-31 | $3.2M | −$966,000 | −23.44% |
| Q4 2011 | 2011-12-31 | $4.1M | −$130,000 | −3.09% |
| Q3 2011 | 2011-09-30 | $4.3M | −$253,000 | −5.61% |
| Q2 2011 | 2011-06-30 | $4.2M | −$854,000 | −16.85% |
| Q1 2011 | 2011-03-31 | $4.1M | −$1.2M | −22.62% |
| Q4 2010 | 2010-12-31 | $4.2M | — | — |
| Q3 2010 | 2010-09-30 | $4.5M | −$1.1M | −19.93% |
| Q2 2010 | 2010-06-30 | $5.1M | — | — |
| Q1 2010 | 2010-03-31 | $5.3M | — | — |
| Q3 2009 | 2009-09-30 | $5.6M | — | — |
Alnylam Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Alnylam Pharmaceuticals's stock-based compensation increased from $139.9M to $348.2M, a change of $208.4M. The latest reported quarter, Q2 2026, shows $86.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗